Comparison	O
with	O
alkaline	B-GENE
phosphatases	I-GENE
and	O
5	B-GENE
-	I-GENE
nucleotidase	I-GENE


Serum	B-GENE
gamma	I-GENE
glutamyltransferase	I-GENE
in	O
the	O
diagnosis	O
of	O
liver	O
disease	O
in	O
cattle	O
.	O


By	O
contrast	O
,	O
secretory	B-GENE
HI	I-GENE
antibodies	I-GENE
were	O
not	O
demonstrated	O
at	O
the	O
onset	O
of	O
illness	O
in	O
any	O
of	O
the	O
patients	O
,	O
but	O
their	O
formation	O
started	O
early	O
and	O
the	O
antibodies	O
reached	O
maximal	O
levels	O
about	O
10	O
days	O
after	O
onset	O
of	O
illness	O
.	O


SGPT	B-GENE
,	O
SGOT	B-GENE
,	O
and	O
alkaline	B-GENE
phosphatase	I-GENE
concentrations	O
were	O
essentially	O
normal	O
in	O
all	O
subjects	O
.	O


Gamma	B-GENE
glutamyl	I-GENE
transpeptidase	I-GENE
(	O
GGTP	B-GENE
)	O
activity	O
in	O
the	O
seminal	O
fluid	O


Studies	O
on	O
immunoglobulin	B-GENE
E	I-GENE
:	O
the	O
impact	O
of	O
a	O
sojourn	O
with	O
Professor	O
Dan	O
H	O
.	O


Ten	O
out	O
-	O
patients	O
with	O
pustulosis	O
palmaris	O
et	O
plantaris	O
were	O
examined	O
with	O
direct	O
immunofluorescence	O
(	O
IF	O
)	O
technique	O
for	O
deposition	O
of	O
fibrinogen	B-GENE
,	O
fibrin	B-GENE
or	O
its	O
degradation	O
products	O
(	O
FR	B-GENE
-	I-GENE
antigen	I-GENE
)	O
in	O
affected	O
and	O
unaffected	O
skin	O
,	O
together	O
with	O
heparin	O
-	O
precipitable	O
fraction	O
(	O
HPF	O
)	O
,	O
cryoglobulin	B-GENE
and	O
total	O
plasma	O
fibrinogen	B-GENE
in	O
the	O
blood	O
.	O


A	O
mixture	O
of	O
human	B-GENE
albumin	I-GENE
5	O
%	O
and	O
hydroxy	O
-	O
ethyl	O
-	O
starch	O
was	O
used	O
as	O
a	O
solution	O
for	O
dilution	O
.	O


Albumin	B-GENE
and	O
cyclic	O
AMP	O
levels	O
in	O
peritoneal	O
fluids	O
in	O
the	O
child	O


On	O
the	O
other	O
hand	O
factor	B-GENE
IX	I-GENE
activity	O
is	O
decreased	O
in	O
coumarin	O
treatment	O
with	O
factor	B-GENE
IX	I-GENE
antigen	O
remaining	O
normal	O
.	O


Aspirin	O
intolerance	O
:	O
unaltered	O
susceptibility	O
of	O
platelet	B-GENE
cyclo	I-GENE
-	I-GENE
oxygenase	I-GENE
to	O
inhibition	O
by	O
aspirin	O
in	O
vitro	O
.	O


Native	O
human	B-GENE
fibrinogen	I-GENE
was	O
brought	O
to	O
coagulation	O
by	O
adding	O
thrombin	B-GENE
.	O


Ectopic	O
ACTH	B-GENE
syndrome	O
and	O
medullary	O
thyroid	O
carcinoma	O
.	O


A	O
striking	O
finding	O
in	O
all	O
of	O
the	O
studies	O
was	O
a	O
positive	O
correlation	O
between	O
PI	O
ACTH	B-GENE
and	O
MSH	B-GENE
contents	O
.	O


The	O
incidence	O
of	O
hepatitis	B-GENE
B	I-GENE
antigen	I-GENE
following	O
transfusion	O
was	O
about	O
2	O
.	O
8	O
per	O
cent	O
.	O


The	O
decline	O
in	O
the	O
activity	O
of	O
cytochrome	B-GENE
oxidase	I-GENE
,	O
peroxidase	B-GENE
and	O
in	O
the	O
lipid	O
content	O
of	O
peripheral	O
neutrophils	O
was	O
followed	O
by	O
a	O
decrease	O
in	O
the	O
phagocytic	O
activity	O
.	O


In	O
both	O
these	O
respects	O
,	O
however	O
,	O
the	O
DBP	B-GENE
mRNA	I-GENE
resembles	O
the	O
late	O
messengers	O
of	O
SV40	O
and	O
polyoma	O
viruses	O
.	O


Serum	B-GENE
ACTH	I-GENE
did	O
not	O
respond	O
to	O
insulin	B-GENE
and	O
metyrapone	O
.	O


Gamma	B-GENE
glutamyl	I-GENE
transpeptidase	I-GENE
activity	O
was	O
increased	O
up	O
to	O
15	O
times	O
above	O
the	O
upper	O
normal	O
limit	O
in	O
children	O
,	O
who	O
received	O
aminopyrine	O
for	O
two	O
weeks	O
or	O
longer	O
.	O


The	O
sequences	O
following	O
the	O
X	O
.	O
borealis	O
oocyte	O
and	O
somatic	O
5S	B-GENE
genes	I-GENE
are	O
identical	O
in	O
12	O
of	O
the	O
first	O
14	O
residues	O
and	O
contain	O
two	O
or	O
more	O
T	O
clusters	O
,	O
as	O
does	O
the	O
corresponding	O
region	O
of	O
X	B-GENE
.	I-GENE
laevis	I-GENE
oocyte	I-GENE
5S	I-GENE
DNA	I-GENE
.	O


High	O
levels	O
of	O
serum	O
calcitonin	B-GENE
were	O
found	O
in	O
patients	O
with	O
chronic	O
renal	O
failure	O
.	O


The	O
response	O
of	O
serum	B-GENE
GH	I-GENE
to	O
arginine	O
infusion	O
was	O
normal	O
,	O
while	O
that	O
to	O
insulin	B-GENE
-	O
induced	O
hypoglycemia	O
was	O
poor	O
.	O


Hepatic	O
oxygen	O
supply	O
and	O
selected	O
blood	O
parameters	O
were	O
recorded	O
in	O
fasted	O
male	O
rates	O
given	O
20	O
-	O
-	O
30	O
mg	O
/	O
kg	O
Escherichia	B-GENE
coli	I-GENE
endotoxin	I-GENE
intraperitoneally	O
.	O


Basal	O
FSH	B-GENE
and	O
LH	B-GENE
levels	O
were	O
significantly	O
lower	O
in	O
addicts	O
;	O
after	O
GnRH	B-GENE
stimulation	O
the	O
addicts	O
'	O
FSH	B-GENE
and	O
LH	B-GENE
values	O
increased	O
but	O
not	O
significantly	O
compared	O
to	O
controls	O
.	O


In	O
this	O
article	O
,	O
the	O
clinical	O
actions	O
of	O
the	O
principal	O
dopamine	B-GENE
receptor	I-GENE
stimulating	O
agents	O
(	O
apomorphine	O
and	O
its	O
derivatives	O
;	O
piribedil	O
,	O
rye	O
-	O
ergot	O
derivatives	O
)	O
are	O
discussed	O
on	O
the	O
basis	O
of	O
their	O
biochemical	O
and	O
pharmacological	O
properties	O
.	O


Thus	O
,	O
the	O
inhibition	O
of	O
pepsin	B-GENE
in	O
human	O
gastric	O
juice	O
does	O
not	O
appear	O
to	O
have	O
a	O
major	O
influence	O
on	O
the	O
healing	O
of	O
duodenal	O
ulcer	O
.	O


Plasma	O
ion	O
changes	O
in	O
venous	O
blood	O
incubated	O
with	O
beta	B-GENE
receptor	I-GENE
blockers	O
and	O
subjected	O
to	O
tonometry	O
in	O
vitro	O
.	O


Such	O
marked	O
differences	O
are	O
found	O
occasionally	O
in	O
the	O
literature	O
:	O
heterophile	O
antibodies	O
against	O
bovine	B-GENE
gammaglobulin	I-GENE
are	O
regarded	O
as	O
responsible	O
for	O
the	O
interference	O
in	O
the	O
Sephadex	O
system	O
of	O
RIST	O
.	O


The	O
preferential	O
serum	B-GENE
IgA	I-GENE
response	O
observed	O
in	O
the	O
patient	O
population	O
suggests	O
that	O
bronchial	O
associated	O
lymphoid	O
tissue	O
in	O
the	O
diseased	O
lung	O
is	O
an	O
important	O
source	O
of	O
circulating	O
IgA	B-GENE
.	O


A	O
rise	O
of	O
hemoglobin	B-GENE
concentration	O
accompanied	O
by	O
an	O
increase	O
of	O
the	O
total	O
iron	O
in	O
the	O
blood	O
serum	O
of	O
white	O
mice	O
was	O
found	O
under	O
oxygen	O
pressure	O
of	O
4	O
atm	O
for	O
an	O
hour	O
(	O
preconvulsive	O
state	O
)	O
and	O
6	O
atm	O
(	O
convulsive	O
state	O
)	O
.	O


It	O
is	O
concluded	O
that	O
opiate	B-GENE
receptors	I-GENE
bordering	O
the	O
fourth	O
cerebral	O
ventricle	O
mediate	O
the	O
cardiovascular	O
and	O
hypnotic	O
action	O
of	O
fentanyl	O
.	O


Urinary	O
excretion	O
of	O
oestrone	O
,	O
oestradiol	O
-	O
17	O
beta	O
and	O
oestriol	O
in	O
pregnancies	O
complicated	O
by	O
steroid	B-GENE
sulphatase	I-GENE
deficiency	O
.	O


On	O
the	O
role	O
of	O
transferrin	B-GENE
in	O
the	O
uptake	O
of	O
gallium	O
by	O
tumor	O
cells	O
.	O


Screening	O
of	O
asthma	O
patients	O
by	O
determination	O
of	O
IgE	B-GENE
and	O
by	O
comprehension	O
of	O
spectrum	O
of	O
allergospecific	B-GENE
IgE	I-GENE
antibodies	I-GENE


In	O
girls	O
prolactin	B-GENE
levels	O
rise	O
at	O
stage	O
2	O
,	O
and	O
are	O
higher	O
after	O
menarche	O
;	O
in	O
boys	O
there	O
is	O
no	O
change	O
in	O
prolactin	B-GENE
levels	O
.	O


Such	O
an	O
hemoglobin	B-GENE
solution	O
was	O
shown	O
to	O
exhibit	O
a	O
high	O
affinity	O
for	O
oxygen	O
and	O
a	O
low	O
Bohr	O
effect	O
(	O
assessed	O
from	O
the	O
delta	O
log	O
Po2	O
/	O
delta	O
pH	O
ratio	O
)	O
.	O


A	O
decrease	O
of	O
the	O
lysozyme	B-GENE
activity	O
coincided	O
with	O
the	O
clinical	O
improvement	O
of	O
the	O
bacterial	O
meningitis	O
.	O


The	O
multiple	O
factors	O
affecting	O
plasma	O
renin	B-GENE
activity	O
in	O
essential	O
hypertension	O
.	O


Analysis	O
of	O
liver	O
biopsy	O
specimens	O
from	O
patients	O
with	O
hepatitis	O
showed	O
a	O
large	O
variation	O
in	O
the	O
mean	O
iron	O
content	O
of	O
the	O
liver	O
ferritin	B-GENE
molecules	O
.	O


Angiotensin	B-GENE
effect	O
in	O
the	O
human	O
kidney	O
.	O


Value	O
of	O
determination	O
of	O
alkaline	B-GENE
phosphatase	I-GENE
isoenzymes	I-GENE
for	O
differential	O
diagnosis	O
of	O
obstructive	O
jaundice	O
and	O
biliary	O
liver	O
cirrhosis	O


Treatment	O
of	O
hypertension	O
with	O
a	O
combination	O
of	O
the	O
adrenergic	B-GENE
beta	I-GENE
receptor	I-GENE
blockader	O
,	O
obsidan	O
,	O
and	O
the	O
vasodilator	O
,	O
apressin	O


Serum	B-GENE
relaxin	I-GENE
levels	O
in	O
prostaglandin	O
E2	O
induced	O
abortions	O
.	O


Carcinoembryonic	B-GENE
antigen	I-GENE
(	O
CEA	B-GENE
)	O
procedures	O
and	O
clinical	O
evaluation	O
.	O


Rheumatoid	B-GENE
factor	I-GENE
and	O
antinuclear	O
antibody	O
tests	O
were	O
frequently	O
positive	O
,	O
and	O
reactions	O
to	O
gold	O
therapy	O
were	O
more	O
frequent	O
than	O
in	O
other	O
rheumatoid	O
populations	O
.	O


Recurrence	O
of	O
bladder	O
tumors	O
among	O
the	O
original	O
9	O
cases	O
has	O
occurred	O
only	O
among	O
the	O
5	O
whose	O
properdin	B-GENE
levels	O
remained	O
below	O
the	O
median	O
.	O


Treatment	O
with	O
heparin	O
,	O
plasminogen	B-GENE
activators	O
and	O
fibrinogenolytic	O
agents	O
was	O
disappointing	O
although	O
renal	O
function	O
has	O
stabilized	O
in	O
one	O
patient	O
on	O
long	O
term	O
oral	O
anticoagulant	O
therapy	O
.	O


The	O
morphological	O
effects	O
of	O
two	O
snake	O
venoms	O
,	O
N	O
.	O
naja	O
and	O
A	O
.	O
piscivorus	O
,	O
and	O
of	O
the	O
Direct	B-GENE
Lytic	I-GENE
Factor	I-GENE
and	O
Phospholipase	B-GENE
-	I-GENE
A	I-GENE
,	O
compounds	O
purified	O
from	O
N	O
.	O
naja	O
crude	O
venom	O
,	O
were	O
investigated	O
on	O
lung	O
and	O
cremaster	O
vessels	O
of	O
rats	O
.	O


Possibility	O
of	O
a	O
TSH	B-GENE
-	O
Screening	O
method	O
for	O
detection	O
of	O
hypothyroidism	O
in	O
the	O
newborn	O


RESULTS	O
:	O
Total	O
IgE	B-GENE
levels	O
showed	O
a	O
tendency	O
to	O
diminish	O
.	O


The	O
neuroleptic	O
-	O
induced	O
increase	O
in	O
central	O
DA	O
turnover	O
(	O
an	O
indicator	O
for	O
the	O
degree	O
of	O
DA	B-GENE
receptor	I-GENE
blocking	O
)	O
was	O
found	O
to	O
be	O
positively	O
correlated	O
with	O
the	O
therapeutic	O
effect	O
of	O
neuroleptics	O
and	O
the	O
development	O
of	O
hypokinetic	O
-	O
rigid	O
symptoms	O
.	O


Mean	O
corpuscular	B-GENE
hemoglobin	I-GENE
concentrations	O
remained	O
normal	O
for	O
48	O
h	O
and	O
then	O
decreased	O
in	O
both	O
groups	O
,	O
the	O
CO2	O
group	O
showing	O
the	O
larger	O
decrease	O
.	O


The	O
effect	O
of	O
calcitonin	B-GENE
,	O
a	O
large	O
amount	O
of	O
calcium	O
given	O
orally	O
,	O
pentagastrin	O
and	O
glucagon	B-GENE
on	O
plasma	O
47Ca	O
radioactivity	O
curves	O
in	O
subjects	O
pretreated	O
with	O
47Ca	O
was	O
examined	O
.	O


Since	O
myoglobin	B-GENE
is	O
co	O
-	O
extracted	O
with	O
the	O
hemoglobin	B-GENE
,	O
the	O
2	O
heme	O
pigments	O
are	O
separated	O
in	O
one	O
portion	O
of	O
the	O
extract	O
by	O
precipitating	O
the	O
hemoglobin	B-GENE
in	O
an	O
85	O
%	O
(	O
NH4	O
)	O
2SO4	O
solution	O
.	O


These	O
studies	O
have	O
shown	O
that	O
the	O
majority	O
of	O
tested	O
staphylococci	O
were	O
resistant	O
to	O
penicillin	O
G	O
,	O
erythromycin	O
,	O
and	O
produced	O
beta	B-GENE
-	I-GENE
lactamase	I-GENE
.	O


The	O
second	O
and	O
third	O
responded	O
similarly	O
to	O
either	O
a	O
combined	O
cyclophosphamide	O
+	O
antilymphocyte	B-GENE
globulin	I-GENE
(	O
ALG	B-GENE
)	O
treatment	O
or	O
to	O
ALG	B-GENE
administration	O
preceded	O
by	O
a	O
small	O
dosage	O
of	O
cyclophosphamide	O
,	O
which	O
had	O
proved	O
ineffective	O
when	O
administered	O
alone	O
.	O


Lymphocyte	O
subpopulations	O
,	O
serum	B-GENE
IgE	I-GENE
and	O
total	O
eosinophil	O
counts	O
in	O
patients	O
with	O
bronchial	O
asthma	O
.	O


IgG	B-GENE
levels	O
of	O
1	O
/	O
100	O
were	O
present	O
in	O
only	O
four	O
out	O
of	O
ten	O
samples	O
obtained	O
150	O
days	O
after	O
the	O
clinical	O
onset	O
.	O


The	O
other	O
hypoglycaemic	O
patient	O
showed	O
an	O
exaggerated	O
insulin	B-GENE
release	O
in	O
response	O
to	O
tolbutamide	O
.	O


Glucose	B-GENE
-	I-GENE
6	I-GENE
-	I-GENE
phosphate	I-GENE
dehydrogenase	I-GENE
(	O
G	B-GENE
-	I-GENE
6	I-GENE
-	I-GENE
PD	I-GENE
)	O
deficiency	O
in	O
the	O
newborn	O
.	O


The	O
routine	O
administration	O
of	O
fat	O
-	O
soluble	O
vitamins	O
appears	O
unnecessary	O
but	O
it	O
is	O
prudent	O
to	O
measure	O
prothrombin	B-GENE
time	O
and	O
serum	O
vitamins	O
A	O
and	O
E	O
at	O
intervals	O
.	O


Association	O
with	O
HL	B-GENE
-	I-GENE
A	I-GENE
W	I-GENE
-	I-GENE
27	I-GENE
.	O


Generally	O
,	O
a	O
correlation	O
was	O
observed	O
between	O
highest	O
concentrations	O
of	O
CSF	B-GENE
immunoglobulins	I-GENE
and	O
degree	O
of	O
meningeal	O
inflammatory	O
response	O
,	O
even	O
if	O
this	O
was	O
a	O
component	O
of	O
other	O
neurological	O
diseases	O
.	O


3	O
activities	O
of	O
the	O
factor	B-GENE
II	I-GENE
molecule	O
in	O
the	O
newborn	O
infant	O
at	O
term	O


One	O
site	O
,	O
PAL	B-GENE
,	O
occurs	O
within	O
the	O
10	O
bp	O
sequence	O
GGGGAGGAGG	O
.	O


Here	O
we	O
describe	O
and	O
map	O
two	O
more	O
new	O
genes	O
identified	O
as	O
allele	O
-	O
specific	O
suppressors	O
that	O
compensate	O
for	O
carboxy	O
-	O
terminal	O
truncation	O
of	O
PET122	B-GENE
.	O


Rabbit	B-GENE
skeletal	I-GENE
muscle	I-GENE
glycogenin	I-GENE
.	O


Characterization	O
of	O
the	O
human	B-GENE
gene	I-GENE
encoding	I-GENE
cytokeratin	I-GENE
17	I-GENE
and	O
its	O
expression	O
pattern	O
.	O


A	O
statistically	O
significant	O
improvement	O
due	O
to	O
the	O
administration	O
of	O
Bromergon	O
was	O
observed	O
in	O
symptoms	O
associated	O
with	O
overreactiveness	O
to	O
normal	O
prolactin	B-GENE
levels	O
,	O
i	O
.	O
e	O
.	O
abdominal	O
tension	O
,	O
edema	O
,	O
weight	O
gain	O
and	O
breast	O
tenderness	O
.	O


This	O
analysis	O
,	O
together	O
with	O
a	O
consideration	O
of	O
the	O
SCBs	O
found	O
upstream	O
of	O
known	O
SWI4	B-GENE
,	I-GENE
6	I-GENE
-	O
dependent	O
genes	O
,	O
leads	O
to	O
the	O
proposal	O
of	O
a	O
revised	O
consensus	O
sequence	O
for	O
this	O
important	O
regulatory	O
element	O
.	O


Synergistic	O
transactivation	O
of	O
the	O
BMRF1	B-GENE
promoter	I-GENE
by	O
the	O
Z	B-GENE
/	O
c	B-GENE
-	I-GENE
myb	I-GENE
combination	O
appears	O
to	O
involve	O
direct	O
binding	O
by	O
the	O
Z	B-GENE
protein	I-GENE
but	O
not	O
the	O
c	B-GENE
-	I-GENE
myb	I-GENE
protein	I-GENE
.	O


The	O
cellular	O
sequences	O
5	O
'	O
to	O
the	O
viral	O
integration	O
site	O
exhibited	O
85	O
to	O
97	O
%	O
identity	O
to	O
several	O
sequences	O
belonging	O
to	O
the	O
mouse	B-GENE
L1	I-GENE
family	I-GENE
of	O
long	O
interspersed	O
repetitive	O
sequences	O
.	O


The	O
predicted	O
receptor	O
structure	O
includes	O
a	O
cysteine	O
-	O
rich	O
extracellular	O
domain	O
,	O
a	O
single	O
hydrophobic	O
transmembrane	O
domain	O
,	O
and	O
a	O
predicted	O
cytoplasmic	B-GENE
serine	I-GENE
/	I-GENE
threonine	I-GENE
kinase	I-GENE
domain	I-GENE
.	O


Drosophila	B-GENE
UbcD1	I-GENE
encodes	O
a	O
highly	O
conserved	O
ubiquitin	B-GENE
-	O
conjugating	O
enzyme	O
involved	O
in	O
selective	O
protein	O
degradation	O
.	O


The	O
goal	O
of	O
the	O
present	O
study	O
was	O
to	O
determine	O
the	O
feasibility	O
of	O
retrovirus	O
mediated	O
expression	O
of	O
rp47phox	B-GENE
in	O
the	O
HL60	O
and	O
U937	O
human	O
hematopoietic	O
cell	O
lines	O
,	O
and	O
in	O
an	O
Epstein	O
-	O
Barr	O
virus	O
transformed	O
B	O
-	O
lymphocyte	O
cell	O
line	O
(	O
EBV	O
-	O
BCL	O
)	O
derived	O
from	O
a	O
p47phox	B-GENE
-	O
deficient	O
CGD	O
patient	O
.	O


Myogenic	O
differentiation	O
can	O
be	O
inhibited	O
by	O
the	O
adenovirus	O
E1a	B-GENE
protein	I-GENE
in	O
the	O
rat	O
L6	O
muscle	O
cell	O
line	O
.	O


Interestingly	O
,	O
the	O
IR5	B-GENE
ORF	I-GENE
of	O
EHV	O
-	O
1	O
possesses	O
a	O
sequence	O
of	O
13	O
amino	O
acids	O
(	O
CAYWCCLGHAFAC	O
)	O
that	O
is	O
a	O
perfect	O
match	O
to	O
the	O
consensus	O
zinc	O
finger	O
motif	O
(	O
C	O
-	O
X2	O
-	O
4	O
-	O
C	O
-	O
X2	O
-	O
15	O
-	O
C	O
/	O
H	O
-	O
X2	O
-	O
4	O
-	O
C	O
/	O
H	O
)	O
.	O


These	O
results	O
indicate	O
that	O
an	O
internal	O
short	O
element	O
located	O
at	O
the	O
very	O
5	O
'	O
terminal	O
of	O
L1	B-GENE
sequence	I-GENE
and	O
the	O
nuclear	O
factor	O
binding	O
to	O
the	O
element	O
play	O
a	O
crucial	O
role	O
in	O
the	O
transcription	O
of	O
human	B-GENE
L1	I-GENE
.	O


Tumor	O
cells	O
were	O
focally	O
immunoreactive	O
for	O
neuron	B-GENE
-	I-GENE
specific	I-GENE
enolase	I-GENE
,	O
insulin	B-GENE
,	O
glucagon	B-GENE
and	O
VIP	B-GENE
.	O


To	O
define	O
the	O
number	O
and	O
nature	O
of	O
the	O
E6	B-GENE
and	O
E7	B-GENE
gene	I-GENE
products	O
expressed	O
in	O
BPV	O
-	O
1	O
-	O
transformed	O
cells	O
,	O
we	O
performed	O
immunoprecipitation	O
experiments	O
with	O
antisera	O
raised	O
to	O
bacterially	O
expressed	O
BPV	B-GENE
-	I-GENE
1	I-GENE
E6	I-GENE
and	O
E7	B-GENE
fusion	I-GENE
proteins	I-GENE
.	O


A	O
third	O
prominent	O
component	O
of	O
apparent	O
molecular	O
mass	O
16	O
kDa	O
displayed	O
several	O
properties	O
,	O
including	O
ability	O
to	O
bind	O
45Ca2	O
+	O
,	O
that	O
are	O
characteristic	O
of	O
the	O
regulatory	O
(	O
B	O
)	O
subunit	O
of	O
mammalian	B-GENE
calcineurin	I-GENE
and	O
was	O
recognized	O
by	O
an	O
antiserum	O
raised	O
against	O
bovine	B-GENE
calcineurin	I-GENE
.	O


Antibodies	O
against	O
this	O
purified	O
protein	O
localize	O
RIM1	B-GENE
to	O
mitochondria	O
.	O


METHODS	O
:	O
IgG	B-GENE
antibodies	I-GENE
vs	O
HHV	O
-	O
6	O
(	O
anti	B-GENE
-	I-GENE
HHV	I-GENE
-	I-GENE
6	I-GENE
-	I-GENE
IgG	I-GENE
)	O
were	O
determined	O
by	O
indirect	O
immunofluorescence	O
in	O
100	O
IVDA	O
(	O
29	O
seronegative	O
and	O
71	O
seropositive	O
for	O
HIV	O
-	O
1	O
of	O
which	O
45	O
were	O
in	O
stage	O
II	O
and	O
26	O
in	O
IV	O
-	O
C1	O
of	O
CDC	O
)	O
as	O
well	O
as	O
in	O
100	O
healthy	O
subjects	O
of	O
a	O
similar	O
age	O
(	O
control	O
group	O
)	O
.	O


Possible	O
roles	O
of	O
RAD5	B-GENE
putative	O
ATPase	B-GENE
/	O
DNA	B-GENE
helicase	I-GENE
activity	O
in	O
DNA	O
repair	O
and	O
in	O
the	O
maintenance	O
of	O
wild	O
-	O
type	O
rates	O
of	O
instability	O
of	O
simple	O
repetitive	O
sequences	O
are	O
discussed	O
.	O


The	O
hit1	B-GENE
-	I-GENE
1	I-GENE
mutation	O
caused	O
a	O
defect	O
in	O
synthesis	O
of	O
a	O
74	B-GENE
-	I-GENE
kD	I-GENE
heat	I-GENE
shock	I-GENE
protein	I-GENE
.	O


The	O
319	O
base	O
pair	O
region	O
immediately	O
upstream	O
of	O
the	O
CAP	O
site	O
is	O
characterized	O
by	O
the	O
lack	O
of	O
a	O
proximal	O
TATA	O
box	O
and	O
the	O
presence	O
of	O
sequences	O
similar	O
to	O
GC	O
boxes	O
,	O
CACCC	O
boxes	O
,	O
CCAAT	O
boxes	O
,	O
activator	B-GENE
protein	I-GENE
2	I-GENE
(	O
Ap	B-GENE
-	I-GENE
2	I-GENE
)	O
sites	O
,	O
partial	O
glucocorticoid	O
response	O
elements	O
(	O
GREs	O
)	O
,	O
and	O
partial	O
cyclic	O
AMP	O
response	O
elements	O
(	O
CREs	O
)	O
.	O


These	O
findings	O
suggest	O
that	O
the	O
MAP	B-GENE
kinase	I-GENE
activator	I-GENE
/	O
MAP	B-GENE
kinase	I-GENE
system	O
may	O
be	O
the	O
downstream	O
components	O
of	O
ras	B-GENE
signal	O
transduction	O
pathways	O
.	O


NSCL	B-GENE
-	I-GENE
1	I-GENE
is	O
expressed	O
in	O
a	O
larger	O
number	O
of	O
these	O
cell	O
lines	O
.	O


A	O
single	O
MEF	B-GENE
-	I-GENE
2	I-GENE
site	I-GENE
is	O
a	O
major	O
positive	O
regulatory	O
element	O
required	O
for	O
transcription	O
of	O
the	O
muscle	O
-	O
specific	O
subunit	O
of	O
the	O
human	B-GENE
phosphoglycerate	I-GENE
mutase	I-GENE
gene	I-GENE
in	O
skeletal	O
and	O
cardiac	O
muscle	O
cells	O
.	O


Intermediate	O
levels	O
of	O
gene	O
activity	O
were	O
observed	O
for	O
TnI	B-GENE
enhancers	I-GENE
containing	O
E	O
-	O
boxes	O
derived	O
from	O
the	O
MCK	B-GENE
left	I-GENE
E	I-GENE
-	I-GENE
box	I-GENE
site	I-GENE
or	O
from	O
the	O
Ig	B-GENE
kappa	I-GENE
E2	I-GENE
E	I-GENE
-	I-GENE
box	I-GENE
.	O


T	B-GENE
-	I-GENE
cell	I-GENE
receptor	I-GENE
beta	I-GENE
(	O
TCR	B-GENE
beta	I-GENE
)	O
gene	O
rearrangements	O
occur	O
in	O
a	O
third	O
of	O
early	O
B	O
-	O
cell	O
acute	O
lymphoblastic	O
leukemias	O
(	O
ALLs	O
)	O
.	O


We	O
have	O
cloned	O
and	O
sequenced	O
COX12	B-GENE
,	O
the	O
nuclear	O
gene	O
for	O
subunit	B-GENE
VIb	I-GENE
of	O
Saccharomyces	B-GENE
cerevisiae	I-GENE
cytochrome	I-GENE
c	I-GENE
oxidase	I-GENE
.	O


The	O
basal	O
promoter	O
elements	O
of	O
murine	B-GENE
cytochrome	I-GENE
c	I-GENE
oxidase	I-GENE
subunit	I-GENE
IV	I-GENE
gene	I-GENE
consist	O
of	O
tandemly	O
duplicated	O
ets	B-GENE
motifs	O
that	O
bind	O
to	O
GABP	B-GENE
-	I-GENE
related	I-GENE
transcription	I-GENE
factors	I-GENE
.	O


Mapping	O
the	O
cAMP	B-GENE
receptor	I-GENE
protein	I-GENE
contact	I-GENE
site	I-GENE
on	O
the	O
alpha	O
subunit	O
of	O
Escherichia	B-GENE
coli	I-GENE
RNA	I-GENE
polymerase	I-GENE
.	O


A	O
major	O
mechanism	O
whereby	O
steroid	B-GENE
hydroxylase	I-GENE
gene	I-GENE
transcription	O
is	O
regulated	O
in	O
the	O
adrenal	O
cortex	O
requires	O
the	O
pituitary	O
peptide	O
hormone	O
,	O
ACTH	B-GENE
,	O
which	O
acts	O
via	O
cAMP	O
.	O


Structure	O
and	O
expression	O
of	O
a	O
gene	O
from	O
Arabidopsis	O
thaliana	O
encoding	O
a	O
protein	O
related	O
to	O
SNF1	B-GENE
protein	O
kinase	O
.	O


We	O
have	O
cloned	O
and	O
characterized	O
a	O
55	O
-	O
kb	O
region	O
of	O
DNA	O
surrounding	O
HRAS1	B-GENE
.	O


An	O
RNA	B-GENE
-	I-GENE
binding	I-GENE
protein	I-GENE
gene	I-GENE
(	O
rbp1	B-GENE
)	O
from	O
Drosophila	O
melanogaster	O
,	O
encoding	O
an	O
RNA	O
recognition	O
motif	O
and	O
an	O
Arg	O
-	O
Ser	O
rich	O
(	O
RS	O
)	O
domain	O
,	O
has	O
been	O
characterized	O
.	O


This	O
mutation	O
also	O
results	O
in	O
markedly	O
decreased	O
levels	O
of	O
CAD	B-GENE
mRNA	I-GENE
and	O
protein	O
in	O
the	O
mutant	O
.	O


Thus	O
,	O
the	O
pol	B-GENE
alpha	I-GENE
-	O
primase	B-GENE
complex	O
appears	O
to	O
act	O
processively	O
for	O
only	O
a	O
short	O
distance	O
.	O


In	O
a	O
retrospective	O
analysis	O
of	O
data	O
from	O
35	O
cases	O
with	O
malignant	O
lymphoma	O
from	O
a	O
cohort	O
of	O
2017	O
HIV	O
-	O
infected	O
patients	O
,	O
the	O
stage	O
of	O
HIV	O
-	O
disease	O
,	O
the	O
CD4	B-GENE
counts	O
at	O
the	O
time	O
of	O
diagnosis	O
,	O
and	O
the	O
use	O
of	O
antineoplastic	O
agents	O
or	O
radiotherapy	O
were	O
correlated	O
with	O
outcome	O
.	O


cDNA	O
clones	O
encoding	O
Arabidopsis	O
thaliana	O
and	O
Zea	B-GENE
mays	I-GENE
mitochondrial	I-GENE
chaperonin	I-GENE
HSP60	B-GENE
and	O
gene	O
expression	O
during	O
seed	O
germination	O
and	O
heat	O
shock	O
.	O


The	O
subunit	O
protein	O
of	O
curli	B-GENE
was	O
highly	O
homologous	O
at	O
its	O
amino	O
terminus	O
to	O
SEF	B-GENE
-	I-GENE
17	I-GENE
,	O
the	O
subunit	O
protein	O
of	O
thin	O
,	O
aggregative	O
fimbriae	O
of	O
Salmonella	O
enteritidis	O
27655	O
strain	O
3b	O
,	O
suggesting	O
that	O
these	O
fibres	O
form	O
a	O
novel	O
class	O
of	O
surface	O
organelles	O
on	O
enterobacteria	O
.	O


The	O
distal	O
portion	O
of	O
the	O
rat	B-GENE
insulin	I-GENE
I	I-GENE
gene	I-GENE
5	I-GENE
'	I-GENE
-	I-GENE
flanking	I-GENE
DNA	I-GENE
contains	O
two	O
sequence	O
elements	O
,	O
the	O
Far	O
and	O
FLAT	O
elements	O
,	O
that	O
can	O
function	O
in	O
combination	O
,	O
but	O
not	O
separately	O
,	O
as	O
a	O
beta	O
-	O
cell	O
-	O
specific	O
transcriptional	O
enhancer	O
.	O


Finally	O
,	O
we	O
determined	O
that	O
the	O
P68	B-GENE
amino	O
terminus	O
was	O
both	O
necessary	O
and	O
sufficient	O
for	O
binding	O
dsRNA	O
as	O
we	O
were	O
able	O
to	O
transfer	O
dsRNA	O
-	O
binding	O
properties	O
to	O
a	O
reporter	O
gene	O
product	O
previously	O
unable	O
to	O
bind	O
RNA	O
.	O


Visual	O
acuity	O
may	O
be	O
decreased	O
by	O
transient	O
changes	O
in	O
refractive	O
error	O
caused	O
by	O
sulfonamides	O
,	O
the	O
antifungal	O
agent	O
metronidazole	O
,	O
thiazide	O
diuretics	O
,	O
and	O
carbonic	B-GENE
anhydrase	I-GENE
inhibitors	O
.	O


Perturbation	O
of	O
dNTP	O
pools	O
also	O
affected	O
the	O
frameshift	O
fidelity	O
of	O
the	O
replicative	O
yeast	B-GENE
DNA	I-GENE
polymerase	I-GENE
alpha	I-GENE
.	O


In	O
addition	O
,	O
the	O
hGCSFR	B-GENE
gene	I-GENE
was	O
chromosomally	O
localized	O
by	O
Southern	O
blot	O
analysis	O
of	O
its	O
segregation	O
pattern	O
in	O
a	O
panel	O
of	O
rodent	O
-	O
human	O
hybrid	O
DNAs	O
using	O
the	O
radiolabeled	O
cDNA	O
probe	O
.	O


These	O
exons	O
,	O
further	O
identified	O
as	O
exons	O
9	O
,	O
10	O
,	O
and	O
11	O
,	O
together	O
encode	O
the	O
37	O
amino	O
acid	O
residues	O
present	O
in	O
alpha	B-GENE
s1	I-GENE
-	I-GENE
casein	I-GENE
variant	I-GENE
A	I-GENE
but	O
missing	O
in	O
variant	O
F	O
.	O


The	O
hydrophobicity	O
plot	O
of	O
NHE	B-GENE
-	I-GENE
3	I-GENE
is	O
very	O
similar	O
to	O
that	O
of	O
NHE	B-GENE
-	I-GENE
1	I-GENE
and	O
NHE	B-GENE
-	I-GENE
2	I-GENE
.	O


We	O
have	O
constructed	O
,	O
using	O
synthetic	O
DNA	O
oligonucleotides	O
,	O
a	O
U14	B-GENE
snRNA	I-GENE
gene	I-GENE
which	O
has	O
been	O
positioned	O
behind	O
a	O
T7	B-GENE
RNA	I-GENE
polymerase	I-GENE
promoter	I-GENE
site	I-GENE
and	O
then	O
inserted	O
into	O
a	O
plasmid	O
.	O


In	O
contrast	O
,	O
tobacco	B-GENE
GS	I-GENE
-	I-GENE
2	I-GENE
is	O
composed	O
of	O
subunits	O
of	O
identical	O
size	O
in	O
all	O
organs	O
examined	O
.	O


Surprisingly	O
,	O
the	O
full	O
-	O
deletion	O
mutant	O
showed	O
a	O
strong	O
block	O
in	O
virus	O
release	O
,	O
suggesting	O
that	O
NC	B-GENE
is	O
involved	O
in	O
virus	O
assembly	O
.	O


Here	O
we	O
demonstrate	O
that	O
the	O
protein	O
product	O
of	O
the	O
ref	B-GENE
-	I-GENE
1	I-GENE
gene	I-GENE
stimulates	O
the	O
DNA	O
binding	O
activity	O
of	O
Fos	B-GENE
-	O
Jun	B-GENE
heterodimers	O
,	O
Jun	B-GENE
-	O
Jun	B-GENE
homodimers	O
and	O
Hela	O
cell	O
AP	B-GENE
-	I-GENE
1	I-GENE
proteins	I-GENE
as	O
well	O
as	O
that	O
of	O
several	O
other	O
transcription	O
factors	O
including	O
NF	B-GENE
-	I-GENE
kappa	I-GENE
B	I-GENE
,	O
Myb	B-GENE
and	O
members	O
of	O
the	O
ATF	B-GENE
/	O
CREB	B-GENE
family	O
.	O


The	O
ARG	B-GENE
SH2	B-GENE
domain	I-GENE
exhibited	O
relatively	O
weak	O
affinity	O
for	O
BCR	B-GENE
and	O
was	O
determined	O
to	O
bind	O
about	O
10	O
-	O
fold	O
less	O
strongly	O
than	O
the	O
ABL	B-GENE
SH2	B-GENE
domain	I-GENE
.	O


Through	O
Southern	O
blot	O
analyses	O
of	O
DNA	O
from	O
backcross	O
and	O
cogenic	O
mice	O
,	O
recombinant	O
inbred	O
strains	O
,	O
and	O
somatic	O
cell	O
hybrids	O
,	O
the	O
genetic	O
loci	O
that	O
produce	O
the	O
cyclin	B-GENE
B1	I-GENE
-	I-GENE
related	I-GENE
sequences	I-GENE
(	O
designated	O
loci	B-GENE
Cycb1	I-GENE
-	I-GENE
rs1	I-GENE
to	O
Cycb1	B-GENE
-	I-GENE
rs9	I-GENE
)	O
were	O
mapped	O
on	O
mouse	O
chromosomes	O
5	O
,	O
1	O
,	O
17	O
,	O
4	O
,	O
14	O
,	O
13	O
,	O
7	O
,	O
X	O
,	O
and	O
8	O
,	O
respectively	O
.	O


The	O
treatment	O
group	O
also	O
showed	O
in	O
vivo	O
T	O
-	O
cell	O
activation	O
with	O
an	O
initial	O
lymphopenia	O
followed	O
by	O
a	O
rebound	O
lymphocytosis	O
and	O
upregulation	O
of	O
the	O
subset	O
markers	O
CD25	B-GENE
(	O
interleukin	B-GENE
2	I-GENE
receptor	I-GENE
)	O
and	O
CD45RO	B-GENE
(	O
T	O
-	O
memory	O
cells	O
)	O
.	O


Urease	B-GENE
activity	O
,	O
judged	O
as	O
the	O
amount	O
of	O
ammonia	O
production	O
from	O
urea	O
,	O
could	O
be	O
measured	O
at	O
25	O
ng	O
per	O
tube	O
(	O
S	O
/	O
N	O
=	O
1	O
.	O
5	O
)	O
with	O
Jack	B-GENE
bean	I-GENE
meal	I-GENE
urease	I-GENE
.	O


Our	O
experiments	O
suggest	O
that	O
the	O
SCL	B-GENE
gene	I-GENE
can	O
be	O
a	O
target	O
for	O
the	O
erythroid	B-GENE
transcription	I-GENE
factor	I-GENE
GATA	I-GENE
-	I-GENE
1	I-GENE
and	O
that	O
the	O
SCL	B-GENE
gene	I-GENE
product	I-GENE
serves	O
as	O
a	O
positive	O
regulator	O
of	O
erythroid	O
differentiation	O
.	O


These	O
temperature	O
-	O
and	O
cold	O
-	O
sensitive	O
strains	O
were	O
used	O
to	O
prepare	O
extracts	O
deficient	O
in	O
BRF1	B-GENE
activity	O
and	O
were	O
tested	O
for	O
transcriptional	O
activity	O
by	O
RNA	B-GENE
polymerases	I-GENE
I	I-GENE
,	I-GENE
II	I-GENE
,	I-GENE
and	I-GENE
III	I-GENE
in	O
vitro	O
.	O


Cleavage	O
by	O
the	O
intron	O
-	O
encoded	O
enzyme	O
(	O
I	B-GENE
-	I-GENE
CreI	I-GENE
)	O
occurs	O
5	O
bp	O
and	O
1	O
bp	O
3	O
'	O
to	O
the	O
intron	O
insertion	O
site	O
(	O
in	O
the	O
3	O
'	O
-	O
exon	O
)	O
in	O
the	O
top	O
(	O
/	O
)	O
and	O
bottom	O
(	O
,	O
)	O
strands	O
,	O
respectively	O
,	O
resulting	O
in	O
4	O
-	O
nt	O
single	O
-	O
stranded	O
overhangs	O
with	O
3	O
'	O
-	O
OH	O
termini	O
.	O


Surprisingly	O
,	O
the	O
Xenopus	B-GENE
U7	I-GENE
gene	I-GENE
contains	O
two	O
adjacent	O
octamer	O
-	O
binding	O
motifs	O
located	O
only	O
12	O
and	O
24	O
bp	O
upstream	O
from	O
the	O
PSE	B-GENE
,	O
instead	O
of	O
the	O
usual	O
location	O
around	O
150	O
-	O
200	O
bp	O
upstream	O
.	O


In	O
humans	O
,	O
four	O
AMP	B-GENE
deaminase	I-GENE
variants	I-GENE
,	O
termed	O
M	B-GENE
(	O
muscle	O
)	O
,	O
L	B-GENE
(	O
liver	O
)	O
,	O
E1	B-GENE
,	O
and	O
E2	B-GENE
(	O
erythrocyte	O
)	O
can	O
be	O
distinguished	O
by	O
a	O
variety	O
of	O
biochemical	O
and	O
immunological	O
criteria	O
.	O


Behind	O
the	O
ATPase	B-GENE
cluster	I-GENE
,	O
two	O
open	O
reading	O
frames	O
were	O
detected	O
that	O
are	O
not	O
homologous	O
to	O
any	O
known	O
chloroplast	O
gene	O
.	O


Using	O
either	O
a	O
p50	B-GENE
-	O
or	O
p65	B-GENE
-	I-GENE
selected	I-GENE
kappa	I-GENE
B	I-GENE
motif	I-GENE
,	O
which	O
displayed	O
differential	O
binding	O
with	O
respect	O
to	O
the	O
other	O
protein	O
,	O
little	O
to	O
no	O
binding	O
was	O
observed	O
with	O
the	O
heterodimeric	B-GENE
NF	I-GENE
-	I-GENE
kappa	I-GENE
B	I-GENE
complex	I-GENE
.	O


However	O
,	O
a	O
cosmid	O
clone	O
containing	O
the	O
entire	O
mouse	B-GENE
alpha	I-GENE
1	I-GENE
(	I-GENE
I	I-GENE
)	I-GENE
gene	I-GENE
,	O
including	O
3	O
.	O
7	O
kb	O
of	O
5	O
'	O
-	O
and	O
4	O
kb	O
of	O
3	O
'	O
-	O
flanking	O
DNA	O
,	O
was	O
expressed	O
at	O
reduced	O
levels	O
in	O
fibroblasts	O
overexpressing	O
oncogenic	B-GENE
ras	I-GENE
.	O


By	O
screening	O
a	O
Y1	O
cell	O
cDNA	O
library	O
with	O
the	O
DNA	O
-	O
binding	O
region	O
of	O
the	O
H	B-GENE
-	I-GENE
2RIIBP	I-GENE
nuclear	I-GENE
hormone	I-GENE
receptor	I-GENE
cDNA	I-GENE
,	O
we	O
isolated	O
a	O
cDNA	O
that	O
is	O
selectively	O
expressed	O
in	O
steroidogenic	O
cells	O
.	O


By	O
using	O
lambda	O
gt11	O
expression	O
cloning	O
with	O
oligonucleotides	O
corresponding	O
to	O
the	O
human	O
immunodeficiency	O
virus	O
1	O
TATA	O
element	O
,	O
we	O
report	O
the	O
identification	O
of	O
a	O
cellular	O
protein	O
with	O
a	O
calculated	O
molecular	O
mass	O
of	O
123	O
kDa	O
that	O
we	O
designate	O
TATA	B-GENE
element	I-GENE
modulatory	I-GENE
factor	I-GENE
(	O
TMF	B-GENE
)	O
.	O


Blood	O
levels	O
of	O
melatonin	O
,	O
serotonin	O
,	O
cortisol	O
,	O
and	O
prolactin	B-GENE
in	O
relation	O
to	O
the	O
circadian	O
rhythm	O
of	O
platelet	O
serotonin	O
uptake	O
.	O


Using	O
5	O
ng	O
/	O
mL	O
as	O
the	O
cutoff	O
,	O
the	O
sensitivity	O
of	O
CEA	B-GENE
was	O
68	O
%	O
.	O


Of	O
the	O
serum	B-GENE
neutralizing	I-GENE
(	I-GENE
SN	I-GENE
)	I-GENE
antibody	I-GENE
negative	O
calves	O
89	O
.	O
7	O
%	O
(	O
26	O
/	O
29	O
)	O
and	O
92	O
.	O
8	O
%	O
(	O
90	O
/	O
97	O
)	O
developed	O
SN	B-GENE
antibody	I-GENE
1	O
month	O
after	O
intranasal	O
and	O
intramuscular	O
vaccination	O
,	O
respectively	O
.	O


A	O
controlled	O
trial	O
of	O
recombinant	B-GENE
human	I-GENE
granulocyte	I-GENE
-	I-GENE
macrophage	I-GENE
colony	I-GENE
-	I-GENE
stimulating	I-GENE
factor	I-GENE
after	O
total	O
body	O
irradiation	O
,	O
high	O
-	O
dose	O
chemotherapy	O
,	O
and	O
autologous	O
bone	O
marrow	O
transplantation	O
for	O
acute	O
lymphoblastic	O
leukemia	O
or	O
malignant	O
lymphoma	O
.	O


The	O
IgG	B-GENE
subclass	O
profile	O
of	O
untreated	O
coeliac	O
disease	O
was	O
found	O
to	O
be	O
the	O
same	O
as	O
in	O
healthy	O
controls	O
(	O
IgG1	B-GENE
approximately	O
IgG2	B-GENE
>	O
IgG3	B-GENE
>	O
IgG4	B-GENE
)	O
,	O
with	O
only	O
the	O
magnitude	O
of	O
the	O
individual	O
subclass	O
responses	O
being	O
increased	O
in	O
coeliac	O
patients	O
.	O


The	O
distinguishing	O
features	O
involved	O
eight	O
amino	O
acid	O
changes	O
,	O
including	O
a	O
single	O
lysine	O
deletion	O
relative	O
to	O
a	O
primate	O
consensus	O
sequence	O
in	O
the	O
first	O
complementary	O
-	O
determing	O
region	O
of	O
V1J1	B-GENE
.	O


On	O
the	O
basis	O
of	O
these	O
unique	O
properties	O
,	O
the	O
newly	O
characterized	O
hemagglutinin	B-GENE
has	O
been	O
termed	O
Limulus	B-GENE
18K	I-GENE
agglutination	I-GENE
-	I-GENE
aggregation	I-GENE
factor	I-GENE
(	O
18K	B-GENE
-	I-GENE
LAF	I-GENE
)	O
.	O


The	O
shift	O
to	O
the	O
nonpermissive	O
temperature	O
is	O
accompanied	O
by	O
the	O
loss	O
of	O
guanyl	O
nucleotide	O
-	O
dependent	O
activity	O
of	O
adenylylcyclase	B-GENE
in	O
vitro	O
.	O


It	O
corresponds	O
to	O
the	O
complete	O
mitochondrial	O
presequence	O
and	O
the	O
lipoyl	O
-	O
bearing	O
domain	O
that	O
are	O
encoded	O
by	O
exons	O
I	O
through	O
IV	O
of	O
the	O
functional	O
E2	B-GENE
gene	I-GENE
.	O


A	O
mutant	O
form	O
of	O
Vps1p	B-GENE
lacking	O
the	O
entire	O
GTP	O
-	O
binding	O
domain	O
interfered	O
with	O
vacuolar	O
protein	O
sorting	O
in	O
wild	O
-	O
type	O
cells	O
.	O


Nucleotide	O
sequence	O
and	O
transcriptional	O
analysis	O
of	O
the	O
polyhedrin	B-GENE
gene	I-GENE
of	O
Spodoptera	O
exigua	O
nuclear	O
polyhedrosis	O
virus	O
.	O


Interferon	B-GENE
type	I-GENE
I	I-GENE
in	O
protective	O
body	O
reactions	O
in	O
an	O
experimental	O
Klebsiella	O
infection	O


No	O
other	O
changes	O
in	O
hematopoietic	O
differentiation	O
status	O
were	O
observed	O
in	O
association	O
with	O
Id	B-GENE
-	I-GENE
SCL	I-GENE
expression	O
.	O


These	O
data	O
indicate	O
that	O
RNK	B-GENE
-	I-GENE
Met	I-GENE
-	I-GENE
1	I-GENE
is	O
a	O
serine	B-GENE
protease	I-GENE
with	O
unique	O
activity	O
that	O
is	O
expressed	O
in	O
the	O
granules	O
of	O
large	O
granular	O
lymphocytes	O
.	O


We	O
describe	O
here	O
17	O
dominant	B-GENE
GCN2	I-GENE
mutations	I-GENE
that	O
lead	O
to	O
derepression	O
of	O
GCN4	B-GENE
expression	O
in	O
the	O
absence	O
of	O
amino	O
acid	O
starvation	O
.	O


In	O
addition	O
,	O
the	O
utility	O
of	O
beta	B-GENE
2	I-GENE
transferrin	I-GENE
assay	O
in	O
the	O
diagnosis	O
of	O
cerebrospinal	O
fluid	O
otorrhea	O
is	O
presented	O
.	O


The	O
structural	O
genes	O
encoding	O
glyceraldehyde	B-GENE
-	I-GENE
3	I-GENE
-	I-GENE
phosphate	I-GENE
dehydrogenase	I-GENE
(	O
GAPDH	B-GENE
)	O
,	O
3	B-GENE
-	I-GENE
phosphoglycerate	I-GENE
kinase	I-GENE
(	O
PGK	B-GENE
)	O
and	O
the	O
N	O
-	O
terminal	O
part	O
of	O
triosephosphate	B-GENE
isomerase	I-GENE
(	O
TIM	B-GENE
)	O
from	O
mesophilic	O
Bacillus	O
megaterium	O
DSM319	O
have	O
been	O
cloned	O
as	O
a	O
gene	O
cluster	O
(	O
gap	B-GENE
operon	I-GENE
)	O
by	O
complementation	O
of	O
an	O
Escherichia	O
coli	O
gap	B-GENE
amber	I-GENE
mutant	I-GENE
.	O


Mono	O
-	O
ADP	O
-	O
ribosylation	O
is	O
a	O
reversible	O
modification	O
of	O
proteins	O
,	O
with	O
NAD	O
:	O
arginine	B-GENE
ADP	I-GENE
-	I-GENE
ribosyltransferases	I-GENE
(	O
EC	B-GENE
2	I-GENE
.	I-GENE
4	I-GENE
.	I-GENE
2	I-GENE
.	I-GENE
31	I-GENE
)	O
and	O
ADP	B-GENE
-	I-GENE
ribosylarginine	I-GENE
hydrolases	I-GENE
(	O
EC	B-GENE
3	I-GENE
.	I-GENE
2	I-GENE
.	I-GENE
2	I-GENE
.	I-GENE
19	I-GENE
)	O
catalyzing	O
the	O
opposing	O
reactions	O
in	O
an	O
ADP	O
-	O
ribosylation	O
cycle	O
.	O


For	O
this	O
reason	O
,	O
the	O
particle	O
forming	O
capacity	O
of	O
derivatives	O
of	O
the	O
HIV	B-GENE
-	I-GENE
1	I-GENE
group	I-GENE
specific	I-GENE
core	I-GENE
antigen	I-GENE
p55	I-GENE
gag	I-GENE
was	O
assayed	O
and	O
compared	O
dependent	O
on	O
various	O
expression	O
systems	O
:	O
recombinant	O
bacteria	O
,	O
vaccinia	O
-	O
and	O
baculoviruses	O
were	O
established	O
encoding	O
the	O
entire	O
core	B-GENE
protein	I-GENE
p55	I-GENE
either	O
in	O
its	O
authentic	O
sequence	O
or	O
lacking	O
the	O
myristylation	O
consensus	O
signal	O
.	O


Removal	O
of	O
beta	B-GENE
2	I-GENE
-	I-GENE
microglobulin	I-GENE
by	O
hemodialysis	O
and	O
hemofiltration	O
:	O
a	O
four	O
year	O
follow	O
up	O
.	O


Truncated	B-GENE
ICSBP	I-GENE
lacking	O
the	O
first	O
33	O
amino	O
-	O
terminal	O
amino	O
acids	O
fails	O
to	O
bind	O
to	O
the	O
ICS	B-GENE
,	O
indicating	O
that	O
at	O
least	O
part	O
of	O
the	O
DNA	O
binding	O
domain	O
is	O
located	O
within	O
the	O
well	O
conserved	O
amino	O
terminus	O
.	O


Therefore	O
,	O
ICSBP	B-GENE
may	O
be	O
involved	O
in	O
maintaining	O
submaximal	O
transcriptional	O
activity	O
of	O
IFN	B-GENE
-	O
inducible	O
genes	O
in	O
hematopoietic	O
cells	O
.	O


A	O
coiled	B-GENE
-	I-GENE
coil	I-GENE
related	I-GENE
protein	I-GENE
specific	O
for	O
synapsed	O
regions	O
of	O
meiotic	O
prophase	O
chromosomes	O
.	O


Interestingly	O
,	O
a	O
portion	O
of	O
the	O
tail	O
domain	O
(	O
aa	O
,	O
1	O
,	O
094	O
-	O
1	O
,	O
830	O
)	O
shares	O
58	O
%	O
amino	O
acid	O
sequence	O
identity	O
with	O
a	O
723	O
-	O
aa	O
protein	O
from	O
mouse	O
brain	O
reported	O
to	O
be	O
a	O
glutamic	B-GENE
acid	I-GENE
decarboxylase	I-GENE
.	O


However	O
,	O
in	O
the	O
subgroup	O
with	O
normal	O
Ht	O
(	O
<	O
0	O
.	O
45	O
l	O
/	O
l	O
;	O
n	O
=	O
201	O
)	O
there	O
was	O
a	O
significant	O
reduction	O
(	O
p	O
<	O
0	O
.	O
05	O
)	O
of	O
the	O
mortality	O
after	O
3	O
months	O
(	O
27	O
%	O
and	O
16	O
%	O
,	O
respectively	O
)	O
and	O
an	O
increase	O
of	O
independence	O
at	O
home	O
(	O
35	O
%	O
and	O
48	O
%	O
,	O
respectively	O
)	O
due	O
to	O
a	O
reduction	O
of	O
the	O
viscosity	O
by	O
means	O
of	O
haemodilution	O
with	O
albumin	B-GENE
(	O
a	O
specific	O
viscosity	O
effect	O
in	O
the	O
normovolaemic	O
group	O
)	O
.	O


RESULTS	O
:	O
In	O
the	O
AGA	O
group	O
,	O
both	O
fetal	O
and	O
maternal	O
serum	O
prolactin	B-GENE
concentration	O
increased	O
significantly	O
with	O
gestation	O
(	O
P	O
<	O
0	O
.	O
001	O
and	O
P	O
<	O
0	O
.	O
01	O
,	O
respectively	O
)	O
.	O


Therefore	O
,	O
the	O
molecular	O
mechanisms	O
of	O
the	O
estrogen	O
action	O
that	O
govern	O
the	O
lactoferrin	B-GENE
gene	I-GENE
expression	O
differ	O
between	O
mouse	O
and	O
human	O
.	O


Four	O
short	O
nucleotide	O
sequences	O
(	O
boxes	O
I	O
to	O
IV	O
)	O
contribute	O
to	O
the	O
light	O
responsiveness	O
of	O
the	O
parsley	B-GENE
chalcone	I-GENE
synthase	I-GENE
promoter	I-GENE
.	O


Exposure	O
to	O
hepatitis	O
B	O
virus	O
in	O
the	O
general	O
population	O
of	O
Hisayama	O
,	O
Japan	O
:	O
significance	O
of	O
isolated	O
antibody	O
to	O
hepatitis	B-GENE
B	I-GENE
surface	I-GENE
antigen	I-GENE
in	O
general	O
population	O
.	O


On	O
the	O
other	O
hand	O
,	O
neither	O
phosphate	O
buffered	O
saline	O
injection	O
into	O
the	O
ES	O
nor	O
primary	O
KLH	B-GENE
challenges	O
of	O
the	O
ES	O
were	O
capable	O
of	O
elevating	O
the	O
threshold	O
level	O
and	O
changing	O
the	O
latency	O
.	O


We	O
show	O
that	O
LexA	B-GENE
-	O
GAL4	B-GENE
and	O
LexA	B-GENE
-	O
Bicoid	B-GENE
fusion	O
proteins	O
are	O
both	O
dependent	O
on	O
SNF2	B-GENE
,	O
SNF5	B-GENE
,	O
and	O
SNF6	B-GENE
for	O
activation	O
of	O
target	O
genes	O
containing	O
one	O
or	O
multiple	O
lexA	B-GENE
operators	I-GENE
.	O


NE	B-GENE
and	O
PR3	B-GENE
assist	O
in	O
the	O
destruction	O
of	O
phagocytosed	O
microorganisms	O
,	O
cleave	O
the	O
important	O
connective	B-GENE
-	I-GENE
tissue	I-GENE
protein	I-GENE
elastin	I-GENE
,	O
and	O
generate	O
chemotactic	O
activities	O
by	O
forming	O
alpha	B-GENE
1	I-GENE
-	I-GENE
proteinase	I-GENE
inhibitor	I-GENE
complexes	I-GENE
and	O
elastin	B-GENE
peptides	I-GENE
.	O


By	O
contrast	O
,	O
d	B-GENE
(	I-GENE
T2AG3T	I-GENE
)	I-GENE
and	O
d	B-GENE
(	I-GENE
T2G4T	I-GENE
)	I-GENE
form	O
only	O
the	O
G	O
-	O
quadruplex	O
monomer	O
structures	O
independent	O
of	O
K	O
cation	O
concentration	O
as	O
reported	O
previously	O
[	O
Sen	O
,	O
D	O
.	O
,	O
&	O
Gilbert	O
,	O
W	O
.	O


Interferon	B-GENE
-	I-GENE
alpha	I-GENE
-	O
induced	O
gene	O
expression	O
:	O
evidence	O
for	O
a	O
selective	O
effect	O
of	O
ouabain	O
on	O
activation	O
of	O
the	O
ISGF3	B-GENE
transcription	I-GENE
complex	I-GENE
.	O


Among	O
the	O
few	O
proteins	O
of	O
the	O
eukaryotic	O
nucleolus	O
that	O
have	O
been	O
characterized	O
,	O
four	O
proteins	O
,	O
nucleolin	B-GENE
,	O
fibrillarin	B-GENE
,	O
SSB1	B-GENE
and	O
NSR1	B-GENE
,	O
possess	O
a	O
common	O
structural	O
motif	O
,	O
the	O
GAR	O
domain	O
,	O
which	O
is	O
rich	O
in	O
glycine	O
and	O
arginine	O
residues	O
.	O


Switching	O
FDC	O
-	O
P1	O
/	O
MAC	O
cells	O
from	O
growth	O
in	O
M	B-GENE
-	I-GENE
CSF	I-GENE
to	O
GM	B-GENE
-	I-GENE
CSF	I-GENE
caused	O
the	O
selective	O
degradation	O
of	O
c	B-GENE
-	I-GENE
fms	I-GENE
mRNA	I-GENE
within	O
6	O
h	O
after	O
factor	O
switching	O
.	O


There	O
was	O
however	O
,	O
no	O
significant	O
difference	O
in	O
the	O
prevalence	O
of	O
chronic	O
respiratory	O
symptoms	O
between	O
animal	O
food	O
workers	O
with	O
positive	O
and	O
negative	O
skin	O
tests	O
to	O
house	O
dust	O
or	O
to	O
fish	O
flour	O
or	O
among	O
those	O
with	O
increased	O
or	O
normal	O
IgE	B-GENE
(	O
except	O
for	O
dyspnea	O
)	O
.	O


Using	O
bovine	B-GENE
and	I-GENE
murine	I-GENE
c	I-GENE
-	I-GENE
myb	I-GENE
clones	O
,	O
no	O
change	O
in	O
the	O
rate	O
of	O
c	B-GENE
-	I-GENE
myb	I-GENE
gene	I-GENE
transcription	O
or	O
mRNA	O
stability	O
was	O
detected	O
during	O
the	O
cell	O
cycle	O
.	O


Moreover	O
,	O
the	O
reconstitution	O
of	O
eUSF	B-GENE
and	O
TFIID	B-GENE
-	O
depleted	O
transcription	O
complexes	O
with	O
purified	O
protein	O
fractions	O
demonstrate	O
that	O
not	O
only	O
TFIID	B-GENE
but	O
also	O
eUSF	B-GENE
essentially	O
participates	O
in	O
complex	O
formation	O
even	O
on	O
H5	B-GENE
promoter	I-GENE
mutations	O
lacking	O
the	O
TATA	O
-	O
box	O
.	O


Nuclear	B-GENE
-	I-GENE
encoded	I-GENE
chloroplast	I-GENE
ribosomal	I-GENE
protein	I-GENE
L12	I-GENE
of	I-GENE
Nicotiana	I-GENE
tabacum	I-GENE
:	O
characterization	O
of	O
mature	O
protein	O
and	O
isolation	O
and	O
sequence	O
analysis	O
of	O
cDNA	O
clones	O
encoding	O
its	O
cytoplasmic	O
precursor	O
.	O


Characterization	O
of	O
these	O
R	O
subunits	O
by	O
their	O
8	O
-	O
azido	O
-	O
cAMP	O
photoaffinity	O
labeling	O
and	O
immunoreactivity	O
,	O
as	O
well	O
as	O
by	O
a	O
phosphorylation	O
-	O
dependent	O
mobility	O
shift	O
on	O
sodium	O
dodecyl	O
sulfate	O
-	O
polyacrylamide	O
gel	O
electrophoresis	O
(	O
SDS	O
-	O
PAGE	O
)	O
,	O
indicated	O
subunit	O
sizes	O
of	O
RII	B-GENE
beta	I-GENE
(	O
53	O
kDa	O
)	O
greater	O
than	O
RII	B-GENE
alpha	I-GENE
dephosphoform	O
(	O
51	O
kDa	O
)	O
greater	O
than	O
RI	B-GENE
alpha	I-GENE
(	O
49	O
kDa	O
)	O
.	O


Within	O
the	O
human	O
enhancer	O
,	O
these	O
two	O
sites	O
are	O
located	O
within	O
the	O
previously	O
defined	O
DNase	B-GENE
I	I-GENE
footprints	I-GENE
,	O
NFAT	B-GENE
-	I-GENE
1	I-GENE
and	O
NFIL	B-GENE
-	I-GENE
2B	I-GENE
,	O
respectively	O
.	O


The	O
cardiac	B-GENE
myosin	I-GENE
light	I-GENE
chain	I-GENE
-	I-GENE
2	I-GENE
(	O
MLC	B-GENE
-	I-GENE
2	I-GENE
)	O
gene	O
promoter	O
contains	O
several	O
positive	O
and	O
negative	O
cis	O
-	O
acting	O
sequences	O
that	O
are	O
involved	O
in	O
the	O
regulation	O
of	O
its	O
expression	O
.	O


Disruption	O
mutations	O
have	O
been	O
constructed	O
in	O
the	O
SLK1	B-GENE
gene	I-GENE
.	O
slk1	B-GENE
null	I-GENE
mutants	I-GENE
cannot	O
grow	O
at	O
37	O
degrees	O
C	O
,	O
but	O
many	O
cells	O
can	O
grow	O
at	O
30	O
,	O
24	O
,	O
and	O
17	O
degrees	O
C	O
.	O


A	O
32P	O
-	O
labeled	O
LAP	B-GENE
DNA	O
-	O
binding	O
and	O
dimerization	O
domain	O
"	O
zipper	O
probe	O
"	O
was	O
used	O
to	O
isolate	O
a	O
clone	O
that	O
encodes	O
a	O
new	O
C	B-GENE
/	I-GENE
EBP	I-GENE
-	I-GENE
homologous	I-GENE
protein	I-GENE
:	O
CHOP	B-GENE
-	I-GENE
10	I-GENE
.	O


Stringent	O
hybridization	O
of	O
EHS	B-GENE
-	I-GENE
1	I-GENE
back	O
to	O
primate	O
genomic	O
DNA	O
indicates	O
two	O
distinct	O
EHS	B-GENE
-	I-GENE
1	I-GENE
loci	I-GENE
in	O
normal	O
human	O
DNA	O
,	O
an	O
identical	O
band	O
pattern	O
in	O
chimpanzee	O
DNA	O
,	O
and	O
a	O
single	O
locus	O
in	O
rhesus	O
monkey	O
DNA	O
.	O


The	O
Caenorhabditis	B-GENE
elegans	I-GENE
vitellogenin	I-GENE
genes	I-GENE
are	O
subject	O
to	O
sex	O
-	O
,	O
stage	O
-	O
,	O
and	O
tissue	O
-	O
specific	O
regulation	O
:	O
they	O
are	O
expressed	O
solely	O
in	O
the	O
adult	O
hermaphrodite	O
intestine	O
.	O


The	O
c	B-GENE
-	I-GENE
Ets	I-GENE
-	I-GENE
1	I-GENE
oncoprotein	I-GENE
is	O
a	O
transcription	O
activator	O
that	O
specifically	O
binds	O
to	O
DNA	O
.	O


Hence	O
temperature	O
and	O
virF	B-GENE
are	O
both	O
required	O
for	O
the	O
induction	O
of	O
the	O
yop	B-GENE
regulon	I-GENE
.	O


To	O
determine	O
the	O
genetic	O
basis	O
for	O
the	O
differences	O
between	O
the	O
cardiac	O
and	O
brain	B-GENE
AE3	I-GENE
variants	I-GENE
,	O
we	O
isolated	O
and	O
characterized	O
the	O
rat	O
gene	O
.	O


Lac	B-GENE
operators	O
were	O
introduced	O
into	O
several	O
positions	O
within	O
the	O
CAB	B-GENE
promoter	I-GENE
and	O
operator	O
-	O
free	O
plasmid	O
was	O
used	O
as	O
control	O
.	O


The	O
SEN1	B-GENE
gene	I-GENE
corresponds	O
to	O
a	O
6	O
,	O
336	O
-	O
bp	O
open	O
reading	O
frame	O
coding	O
for	O
a	O
2	O
,	O
112	O
-	O
amino	O
-	O
acid	O
protein	O
(	O
molecular	O
mass	O
,	O
239	O
kDa	O
)	O
.	O


The	O
IA4	B-GENE
mAb	I-GENE
was	O
identified	O
among	O
a	O
series	O
of	O
antibodies	O
raised	O
in	O
BALB	O
/	O
c	O
mice	O
after	O
immunization	O
against	O
a	O
HLA	B-GENE
class	O
I	O
-	O
deficient	O
,	O
lymphokine	O
-	O
activated	O
killer	O
(	O
LAK	O
)	O
-	O
susceptible	O
EBV	O
-	O
B	O
lymphocyte	O
line	O
.	O


Primer	O
extension	O
and	O
mung	B-GENE
bean	I-GENE
and	I-GENE
S1	I-GENE
nuclease	I-GENE
mapping	O
indicated	O
multiple	O
transcription	O
initiation	O
sites	O
and	O
were	O
consistent	O
with	O
Northern	O
analyses	O
.	O


PSI	B-GENE
-	I-GENE
G	I-GENE
and	O
PSI	B-GENE
-	I-GENE
K	I-GENE
probably	O
have	O
evolved	O
from	O
a	O
gene	O
duplication	O
of	O
an	O
ancestral	O
gene	O
.	O


An	O
experiment	O
examined	O
the	O
effects	O
of	O
treatment	O
with	O
gonadotrophin	B-GENE
releasing	I-GENE
hormone	I-GENE
(	O
100	O
micrograms	O
GnRH	B-GENE
injected	O
24	O
h	O
after	O
progestagen	O
sponge	O
removal	O
)	O
,	O
season	O
of	O
treatment	O
(	O
autumn	O
v	O
.	O
spring	O
)	O
,	O
the	O
effect	O
of	O
supplementary	O
feeding	O
with	O
lupin	O
grain	O
(	O
in	O
autumn	O
only	O
,	O
from	O
12	O
days	O
before	O
until	O
8	O
days	O
after	O
sponge	O
removal	O
)	O
on	O
the	O
time	O
of	O
ovulation	O
in	O
182	O
mature	O
Merino	O
ewes	O
superovulated	O
with	O
a	O
combination	O
of	O
400	O
I	O
.	O
U	O
.	O
pregnant	B-GENE
mare	I-GENE
serum	I-GENE
gonadotrophin	I-GENE
(	O
PMSG	B-GENE
)	O
and	O
12	O
mg	O
follicle	B-GENE
stimulating	I-GENE
hormone	I-GENE
(	O
FSH	B-GENE
-	I-GENE
P	I-GENE
)	O
.	O


STP1	B-GENE
is	O
an	O
unessential	O
yeast	O
gene	O
involved	O
in	O
the	O
removal	O
of	O
intervening	O
sequences	O
from	O
some	O
,	O
but	O
not	O
all	O
,	O
families	O
of	O
intervening	O
sequence	O
-	O
containing	O
pre	O
-	O
tRNAs	O
.	O


Using	O
these	O
antibodies	O
,	O
we	O
were	O
able	O
to	O
define	O
the	O
conditions	O
to	O
completely	O
solubilize	O
the	O
Cdc25	B-GENE
protein	I-GENE
.	O


Disruption	O
demonstrates	O
that	O
CDC14	B-GENE
is	O
an	O
essential	O
gene	O
.	O


Argatroban	O
may	O
be	O
more	O
effective	O
under	O
low	O
HC	B-GENE
II	I-GENE
conditions	O
because	O
of	O
its	O
potent	O
inhibition	O
of	O
thrombin	B-GENE
activity	O
at	O
sites	O
of	O
vascular	O
wall	O
damage	O
.	O


Furthermore	O
,	O
no	O
transcripts	O
of	O
the	O
same	O
size	O
and	O
having	O
the	O
same	O
developmental	O
profile	O
as	O
those	O
generated	O
by	O
the	O
wild	B-GENE
-	I-GENE
type	I-GENE
E10	I-GENE
fragment	I-GENE
were	O
identified	O
by	O
probes	O
covering	O
the	O
remainder	O
of	O
the	O
cloned	O
region	O
.	O


The	O
sequence	O
-	O
specific	O
interaction	O
of	O
nuclear	B-GENE
factor	I-GENE
HiNF	I-GENE
-	I-GENE
D	I-GENE
with	O
this	O
key	O
proximal	O
promoter	O
element	O
of	O
the	O
H4	B-GENE
-	I-GENE
FO108	I-GENE
gene	I-GENE
is	O
cell	O
cycle	O
regulated	O
in	O
normal	O
diploid	O
cells	O
(	O
J	O
.	O


In	O
agreement	O
with	O
this	O
southern	O
blotting	O
of	O
mouse	O
DNA	O
with	O
SmN	B-GENE
probes	O
reveals	O
bands	O
,	O
additional	O
to	O
those	O
derived	O
from	O
the	O
pseudogene	O
,	O
which	O
are	O
characteristic	O
of	O
an	O
intron	O
-	O
containing	O
SmN	B-GENE
gene	I-GENE
.	O


A	O
38	O
-	O
bp	O
poly	O
(	O
dA	O
-	O
dT	O
)	O
region	O
was	O
found	O
to	O
be	O
a	O
positive	O
regulator	O
of	O
Act1	B-GENE
promoter	I-GENE
activity	O
.	O


The	O
DRF	B-GENE
-	I-GENE
2	I-GENE
nuclear	I-GENE
protein	I-GENE
has	O
characteristics	O
similar	O
to	O
those	O
of	O
the	O
muscle	O
-	O
specific	O
regulatory	O
factor	O
,	O
MEF	B-GENE
-	I-GENE
2	I-GENE
(	O
Buskin	O
and	O
Hauschka	O
1989	O
;	O
Gossett	O
et	O
al	O
.	O
,	O
1989	O
)	O
.	O


From	O
the	O
15	O
-	O
kb	O
clone	O
a	O
4	B-GENE
-	I-GENE
kb	I-GENE
EcoRI	I-GENE
fragment	I-GENE
containing	O
the	O
first	O
two	O
exons	O
and	O
2	O
.	O
6	O
kb	O
of	O
the	O
5	O
'	O
flanking	O
region	O
of	O
the	O
opn	B-GENE
gene	I-GENE
was	O
sequenced	O
,	O
and	O
the	O
transcriptional	O
start	O
site	O
determined	O
by	O
primer	O
extension	O
analysis	O
and	O
S1	B-GENE
nuclease	I-GENE
mapping	O
.	O


This	O
open	O
reading	O
frame	O
was	O
confirmed	O
the	O
correct	O
one	O
by	O
direct	O
amino	O
-	O
terminal	O
sequence	O
analysis	O
of	O
the	O
overproduced	O
msgB	B-GENE
gene	I-GENE
product	I-GENE
.	O


The	O
virus	O
encodes	O
a	O
40	O
-	O
kDa	O
protein	O
,	O
tax	B-GENE
,	O
that	O
is	O
important	O
for	O
the	O
immortalization	O
of	O
T	O
cells	O
.	O


However	O
,	O
butyrate	O
was	O
at	O
least	O
2	O
-	O
fold	O
more	O
effective	O
in	O
stimulating	O
CAT	B-GENE
activity	O
of	O
fusion	O
genes	O
containing	O
upstream	O
sequences	O
(	O
-	O
834	O
to	O
-	O
576	O
)	O
than	O
those	O
containing	O
proximal	O
sequences	O
(	O
-	O
456	O
to	O
-	O
172	O
)	O
,	O
suggesting	O
two	O
regions	O
in	O
the	O
PSG1	B-GENE
-	I-GENE
I	I-GENE
gene	I-GENE
that	O
mediate	O
the	O
butyrate	O
response	O
.	O


Recently	O
,	O
the	O
3	B-GENE
.	I-GENE
6	I-GENE
-	I-GENE
kb	I-GENE
full	I-GENE
-	I-GENE
length	I-GENE
alpha	I-GENE
-	I-GENE
GalNAc	I-GENE
cDNA	I-GENE
sequence	I-GENE
was	O
isolated	O
and	O
found	O
to	O
have	O
remarkable	O
nucleotide	O
and	O
predicted	O
amino	O
acid	O
homology	O
(	O
55	O
.	O
8	O
and	O
46	O
.	O
9	O
%	O
,	O
respectively	O
)	O
with	O
the	O
human	B-GENE
alpha	I-GENE
-	I-GENE
galactosidase	I-GENE
A	I-GENE
(	O
alpha	B-GENE
-	I-GENE
Gal	I-GENE
A	I-GENE
)	O
cDNA	O
.	O


All	O
mutant	B-GENE
JCV	I-GENE
T	I-GENE
antigens	I-GENE
bound	O
to	O
JCV	O
and	O
SV40	O
origins	O
of	O
DNA	O
replication	O
.	O


EBNA	B-GENE
-	I-GENE
2	I-GENE
and	O
the	O
cis	O
-	O
acting	O
CD23	B-GENE
element	I-GENE
increased	O
TK	B-GENE
-	O
promoted	O
mRNA	O
and	O
did	O
not	O
alter	O
the	O
herpes	B-GENE
simplex	I-GENE
virus	I-GENE
TK	I-GENE
promoter	I-GENE
transcription	I-GENE
start	I-GENE
site	I-GENE
.	O


